PATENT CLAIM ANALYSIS

Application Number: 16044682
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-12
Patent Classification: ["514", "329000"]

Abstract:
Disclosed herein are compositions and methods for the treatment of pulmonary hypertension, including pulmonary arterial hypertension. The methods include administering to a patient in need thereof an effective amount of cinitapride or derivative thereof. The compositions include an effective amount of cinitapride or derivative thereof, in some instances combined with one or more additional agents for the treatment of pulmonary hypertension.

Claim (Index 34):
The kit of  claim 27 , wherein the at least one other agent comprises:\n an endothelin receptor antagonist comprising bosentan, macitentan, ambrisentan, and sitaxsentan.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 95.0
- Lexical Diversity: 1.69231
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15671653', '12280327', '11576773', '15556607', '15028347']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7666458247512133
- 35 USC 102 Novelty (BERT): 0.5744428823925063
- Combined Prediction Score: 0.7474255305153427
- Mean Citation Score: 353.969998
- Max Citation Score: 640.33344
- Similarity Product: 348.5024743860627

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test